We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sym004 in Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01117428
First Posted: May 5, 2010
Last Update Posted: July 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Symphogen A/S
  Purpose
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.

Condition Intervention Phase
Metastatic Colorectal Cancer Drug: Sym004 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors

Further study details as provided by Symphogen A/S:

Primary Outcome Measures:
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Visit 2 until first follow-up visit (up to 66 weeks) ]
    The AEs were used as a primary endpoint. AEs were summarized using descriptive statistics and presented overall by system organ class and preferred term. The frequencies of AEs were presented including number and percentages of participants with events and the total number of events.


Secondary Outcome Measures:
  • Antitumor Activity [ Time Frame: Up to 62 weeks ]
    Best Overall Response (OR) on the Full Analysis Set (FAS) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, based on central evaluation with confirmatory CT scan or MRI [Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Overall Response (OR): CR + PR]. Baseline was defined as Visit 2 (pre-infusion). The outcome measure was measured from screening until PD.

  • Antitumor Activity Endpoints - Time-to-event Endpoints [ Time Frame: Up to 62 weeks ]

    Median Progression Free Survival (PFS) was defined as the time interval without PD from start of first infusion until death or documented PD (i.e. at least a 20% increase in the sum of diameters of target lesions) according to RECIST v1.1. Patients who died without confirmed PD were considered as progressed. Patients who died or showed PD more than 21 days after last treatment were censored (i.e. were considered alive without progression on Day 21 after last treatment). Patients without events were censored at date of last scan or 22 days after last treatment, whichever occurred first.

    Median Overall Survival (OS) was defined as the time from start of first infusion until date of death from any cause. Patients alive at the time of the analysis or prematurely withdrawn from the trial (e.g. lost to follow-up or consent withdrawn) were censored for the OS analysis. In any case of censoring, the date of censoring was the last time point documenting survival status.


  • Terminal Half-Life (T½) [ Time Frame: See Time Frame in the Outcome Measure Description ]

    For Part A, the endpoint was not calculated. For Parts B, C and F, the endpoint was calculated for each patient following the first and fourth Sym004 infusions.

    For Parts D and E, the endpoint was calculated for each patient following the first and third Sym004 infusions.

    T½ was estimated using non-compartmental methods and actual time points.

    Outcome Measure Time Frame:

    Parts B, C and F (Weekly dosing): Sample collection at Visit 2 (1st dose from end of infusion, 1-, 2-, 4-, 8-, 24-, 48-hours) until 1 week post-infusion (168-hours) and at Visit 5 (4th dose from end of infusion, 1-, 2-, 4-, 8-, 24-hours) until 1 week post-infusion (168-hours).

    Parts D, E (Dosing every second week): Sample collection at Visit 2 (1st dose from end of infusion, 1-, 2-, 4-, 8-, 24-, 48-hours) to end of 3rd dose (from end of infusion, 1-, 2-, 4-, 8-, 24-hours) until 2 weeks post-infusion (336 hours).



Enrollment: 111
Actual Study Start Date: March 2010
Study Completion Date: May 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sym004 Drug: Sym004

In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.

In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.

In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.

In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.

In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.


Detailed Description:

Part A investigates the safety and pharmacokinetics (PK) of escalating weekly dosing of Sym004 in patients with recurrent advanced solid tumors.

Part B and C validates the safety, PK and efficacy of weekly dosing of Sym004 at the maximum tolerated dose (MTD) in a homogenous patient population with advanced metastatic colorectal cancer (mCRC) and wild-type Kirsten rat sarcoma (KRAS). Part B will be initiated when a safe dose has been established in Part A.

If MTD equals 12 mg/kg, then part C will explore the 9 mg/kg level.

Part D and E is to validate the safety, PK and efficacy when administered every 2 weeks at doses of 12 mg/kg and 18 mg/kg, respectively.

Part F is to validate safety, PK and efficacy when administered with a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Part A:

1. Patients with refractory or recurrent advanced late stage solid tumors without available therapeutic options .

Part B, C, D, E and F:

  1. Patients with refractory or recurrent advanced mCRC and wild-type KRAS who have progressed on epidermal growth factor receptor (EGFR) Ab treatment.
  2. Patients wit confirmed response while on treatment anti-EGFR Ab treatment.
  3. Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.
  4. Patients must be willing to have a biopsy performed from a tumor lesion at screening and at Visit 6.

Part A, B, C, D, E and F:

  1. Histologically or cytologically confirmed diagnosis of cancer
  2. Failure and/or intolerance to standard chemotherapy
  3. Life expectancy of at least 3 months
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2

Exclusion Criteria:

  1. Patients with clinically symptomatic brain metastases.
  2. Received the following treatments prior to Visit 2:

    • Cytotoxic or cytostatic anti-cancer chemotherapy within 4 weeks
    • Total resection or irradiation of the target lesion
    • Antibody therapy within 4 weeks and vaccines within 12 weeks
    • Tyrosin kinase inhibitors within 4 weeks
    • Any investigational agent within 4 weeks
  3. Diarrhea CTCAE >1
  4. Skin rash CTCAE >1
  5. Abnormal organ or bone marrow function.
  6. Use of immunosuppressive agents for the past 4 weeks prior to trial start, including systemic corticosteroids used at doses above 20mg/day of prednisolone or equivalent.
  7. History of other malignancy within 5 years prior to trial start, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix (not in Part A).
  8. Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the investigator.
  9. Known HIV positive
  10. Known active hepatitis B or C
  11. Patients with known uncontrolled allergic conditions or allergy to the study drug and/or their components.
  12. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities and controlled and well treated chronic atrial fibrillation.
  13. Significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with effect of the trial drug.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01117428


Locations
United States, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States, 78229
Belgium
UZ Brussel, Medische Oncologie
Brussel, Belgium, 1090
UZ Gasthuisberg, Digestive Oncology Unit
Brussel, Belgium, 3000
UZ Antwerp, Oncologie
Edegem, Belgium, 2650
Spain
Medical Oncology Department, Vall d´Hebron University Hospital
Barcelona, Spain, 08035
Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío
Sevilla, Spain, 41013
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
Symphogen A/S
Investigators
Principal Investigator: Josep Tabernero, MD, PhD Vall d´Hebron University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Symphogen A/S
ClinicalTrials.gov Identifier: NCT01117428     History of Changes
Other Study ID Numbers: Sym004-01
2009-017119-13 ( EudraCT Number )
First Submitted: April 23, 2010
First Posted: May 5, 2010
Results First Submitted: February 3, 2017
Results First Posted: July 12, 2017
Last Update Posted: July 12, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Symphogen A/S:
Advanced solid tumors
Metastatic colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases


To Top